Comment argues HERB is a tiny, loss-making Canadian microcap with speculative upside and no 280E removal catalyst, making it unattractive.
Unpriced research observations (excluded from Calls and Returns):
HERB — AVOID The author describes HERB as a tiny, loss-making Canadian microcap with minimal cash flow and thin liquidity. Its upside story is based on speculative future targets such as export ramps, a $50M run-rate, and potential M&A rather than current fundamentals. Unlike U.S. operators, it lacks the 280E removal catalyst that could improve margins. The author presents this as a reason to avoid the stock. resolved_asset_type_mismatch
Most of the upside story rests entirely on speculative future targets—export ramps, $50M run-rate, and potential M&A.